Clinical Trials

Breast Neoplasms

NCT04301076 2026-03-18

Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)

LymphoidOther hematologic neoplasm

30 enrolled

Lymphoma, HTLV-I Infections, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT04616560 2026-03-18

Trastuzumab Deruxtecan for the Treatment of HER2+ Newly Diagnosed or Recurrent Osteosarcoma

77 enrolled

Sarcoma

Osteosarcoma

NCT04799275 2026-03-18

Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma

Phase 2/3 Suspended

422 enrolled

Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT04840589 2026-03-18

Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors

BreastGastrointestinalGenitourinaryPlasma cell

66 enrolled

Gynecologic

Neoplasm Metastasis, Ovarian Neoplasms

NCT04929041 2026-03-18

Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 Negative

Phase 2/3 Suspended

427 enrolled

Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04955808 2026-03-18

Biospecimen Collection in Identifying Genetic Changes in Patients With Breast, Prostate, Colorectal, Liver, or Kidney Cancer or Multiple Myeloma Undergoing Surgery

Suspended

2,400 enrolled

Breast Neoplasms, Carcinoma, Renal Cell, Colonic Neoplasms, Carcinoma, Hepatocellular, Multiple Myeloma, Prostatic Neoplasms

NCT05223036 2026-03-18

Testing Obeticholic Acid for Familial Adenomatous Polyposis

80 enrolled

Gastrointestinal

Attenuated familial adenomatous polyposis, Duodenal Neoplasms, Adenomatous Polyposis Coli, Colorectal Neoplasms

NCT05372614 2026-03-18

Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene

33 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT05432804 2026-03-18

Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment

Phase 1/2 Suspended

97 enrolled

CNS

Glioblastoma

NCT05554380 2026-03-18

Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With PTEN/AKT Mutations, A ComboMATCH Treatment Trial

33 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT06015880 2026-03-18

Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

30 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT06732401 2026-03-18

Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung Cancer

Phase 3 Suspended

630 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06802523 2026-03-18

Testing the Combination of Targeted Radiotherapy With Anti-Cancer Drugs, Venetoclax and ASTX-727, to Improve Outcomes for Adults With Newly Diagnosed Acute Myeloid Leukemia

Other hematologic neoplasm

53 enrolled

Leukemia, Myeloid, Acute

NCT05111561 2026-03-17

Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer

42 enrolled

Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT07136493 2026-03-05

Circulating Tumor DNA Based Minimal Residual Disease Detection for Patients With Early-Stage Breast Cancer

Phase NA Suspended

350 enrolled

Triple Negative Breast Neoplasms

NCT07025538 2026-02-23

Biomarker-Guided Ruxolitinib for the Prevention of Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell Transplantation

42 enrolled

Hematopoietic and Lymphatic System Neoplasm

NCT06968195 2026-02-10

Autologous CAR T Cells Targeting GPC3 (RPCAR01) for the Treatment of Advanced or Metastatic GPC3 Expressing Hepatocellular Carcinoma

24 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT06492707 2026-02-09

DR-18 for the Treatment of Relapsed or Persistent Acute Myeloid Leukemia or Myelodysplastic Syndrome After Hematopoietic Cell Transplantation, the DR. DREAM Trial

MyeloidOther hematologic neoplasm

20 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT06733350 2026-02-09

Testosterone Replacement Therapy for the Treatment of Low Testosterone in Hypogonadal Men With Localized Prostate Cancer on Active Surveillance

Phase 4 Suspended

600 enrolled

Prostatic Neoplasms

NCT07301268 2026-02-03

GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma

36 enrolled

CNSSarcoma

Astrocytoma, Glioblastoma, Gliosarcoma

NCT06575686 2026-01-21

Epcoritamab and Tazemetostat for the Treatment of Relapsed or Refractory Grade I-IIIa Follicular Lymphoma

33 enrolled

Lymphoma, Follicular

NCT05989828 2026-01-14

A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer

20 enrolled

Triple Negative Breast Neoplasms

NCT06741072 2026-01-08

BZLF1 Peptide Vaccine (OSU-2131) With QS-21 for the Prevention of Epstein-Barr Virus Related Cancer in Patients Awaiting Solid Organ Transplants

55 enrolled

Renal Insufficiency, Chronic

NCT06191575 2025-12-22

7 Tesla MRI Neuroimaging in Testicular Cancer Patients With Hypogonadism and on Androgen Replacement Therapy

Suspended

10 enrolled

Hypogonadism, Testicular Neoplasms

NCT06049576 2025-12-17

Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell Carcinoma

30 enrolled

Carcinoma, Renal Cell

NCT06112847 2025-12-10

Lenalidomide and Epcoritamab for the Treatment of Previously Untreated Follicular Lymphoma

29 enrolled

Lymphoma, Follicular

NCT06454409 2025-11-19

Regorafenib in Combination With Venetoclax and Azacitidine for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia

MyeloidOther hematologic neoplasm

20 enrolled

GATA2 Deficiency, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT04539366 2025-11-03

Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Young Adults With Relapsed/Refractory Osteosarcoma and Neuroblastoma, The GD2-CAR PERSIST Trial

67 enrolled

CNSSarcoma

Neuroblastoma, Osteosarcoma

NCT03575611 2025-10-28

Stereotactic Body Radiation Therapy in Treating Patients With Oligometastatic Renal Cell Carcinoma

123 enrolled